Ernst Lengyel, MD, PhD - 2012 Fletcher Scholar
“Characterization of the Bi-directional Cross Talk Between Cancer Cells and Carcinoma-associated Fibroblasts”
Awarded the 2012 Fletcher Scholars Award
In the past several decades, there has been limited progress in the treatment of ovarian cancer (OvCa) and it remains the most lethal of all gynecologic malignancies. As is the case with most solid tumors, metastasis is the primary contributor to mortality. When OvCa metastasizes, it most often homes to regions within the abdominal cavity like the omentum, a 15x15x3 cm large fat pad within the peritoneal cavity that is rich in stromal cell types including mesothelial cells, adipocytes, and fibroblasts. Once OvCa colonizes in the omentum, the environment shifts to one which supports the growth of OvCa. Eventually, the entire omentum is transformed into solid tumor, which causes grave complications, compressing surrounding organs and causing a bowel obstruction. We believe that the interaction between OvCa and the stromal cell types is key to the progression of this deadly disease.
Dr. Lengyel is an expert in the diagnosis and treatment of gynecologic malignancies--specifically, ovarian, cervical and endometrial cancers. His primary clinical focus is on the treatment of ovarian cancer, including advanced surgical techniques designed to improve patient outcomes. Dr. Lengyel has been recognized by Chicago magazine as one of the city's "Top Doctors" for ovarian and cervical cancer care. He is also skilled in complex pelvic surgeries for benign gynecologic conditions, such as endometriosis and fistula repairs.
This study will use an innovative, systematic approach to discover the signaling changes which occur intracellularly with the interaction of OvCa cells and a crucial stromal component, carcinoma-associated fibroblasts. Once we determine the key signaling pathways, our findings can be used to identify new therapeutic targets for the treatment of ovarian cancer. Indeed, discovery of key
signaling pathways in other cancers, such as Her2/neu in breast cancer, has led to significant advances in treatment.
Dr. Lengyel's research laboratory focuses on the investigation of new therapies for the treatment of ovarian cancer. In addition to clinical and research activities, Dr. Lengyel mentors residents and postdoctoral fellows in the Department of Obstetrics and Gynecology at the University of Chicago.
Learn more about Dr. Lengyel
"I owe a great deal to the Cancer Research Foundation for giving me a head start. This financial help made the difference between my getting a fast and successful start, and my other wise struggling to obtain the necessary funds to get my research program started."Elaine Fuchs, Ph.D.
Professor, Departments of Medicine and Molecular Genetics and Cell Biology and Human Genetics University of Chicago
April 30, 2010